Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
Journal of Cancer Prevention
; : 74-81, 2017.
Article
em En
| WPRIM
| ID: wpr-173854
Biblioteca responsável:
WPRO
ABSTRACT
Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of BCR-ABL1 with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(9:22) (q³⁴:q¹¹). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Fosfotransferases
/
Células-Tronco
/
Translocação Genética
/
Proteínas Tirosina Quinases
/
Cromossomo Filadélfia
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Cromossomos Humanos
/
Citogenética
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Métodos
Limite:
Humans
Idioma:
En
Revista:
Journal of Cancer Prevention
Ano de publicação:
2017
Tipo de documento:
Article